Leadership
The COPDforum leadership is comprised of renowned researchers/clinicians in COPD, who have contributed significantly
to the developments in this field. This global group represents some of the world's thought leaders in this area,
who are prominent in respiratory publications, international and local societies and research initiatives. Click on the
links below to learn more about the COPDforum leadership.
Leadership
Peter M. A. Calverley
MB,ChB, FRCP, Professor of Pulmonary and Rehabilitation Medicine
United Kingdom
COPDforum offers an excellent educational resource for all those involved in understanding the
... Read AllCOPDforum offers an excellent educational resource for all those involved in understanding the causes and treatment of COPD which will allow its users to raise the profile of this important but often neglected disease
Place of work
The University of Liverpool.
Experience
Peter Calverley is Professor of Pulmonary and Rehabilitation
Medicine at the University of Liverpool and Honorary Consultant
Respiratory Physician at the Aintree Hospitals, Liverpool. He
qualified from the University of Edinburgh in 1973 and was made a
Fellow of the Royal College of Physicians of both London and
Edinburgh in 1990.
Professor Calverley was Associate Editor of the European
Respiratory Journal between 2000 and 2005, and Associate Editor of
Thorax between 1990 and 1995, and from 2004 to date. He was also
Editor of Clinical Science between 2002 and 2004. He has been a
member of the Editorial Board of the American Journal of
Respiratory and Critical Care Medicine since 2002.
Professor Calverley is the author of numerous papers of which
some of the most recent are listed below.
Recent publications
Calverley PM, Anderson JA, Celli B, Ferguson
GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators.
Salmeterol and fluticasone propionate and survival in chronic
obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
Calverley PM, Sanchez-Toril F, McIvor A,
Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment
with roflumilast in severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2007;176:154-61.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA,
Calverley P, Fukuchi Y, Jenkins C,
Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for
Chronic Obstructive Lung Disease. Global strategy for the
diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care
Med 2007;176:532-55.
Calverley PM, Rennard SI. What have we learned
from large drug treatment trials in COPD? Lancet
2007;370:774-85.
Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA,
Hruska N, Korber W, Buchner B, Criee CP, Hasenfuss G,
Calverley P. Angiotensin II blockers in
obstructive pulmonary disease. A randomized, controlled trial. Eur
Respir J 2006;27(5):972-9.
Laude EA, Duffy NC, Baveystock C, Dougill B, Campbell MJ, Lawson
R, Jones PW, Calverley PM. The Effect of Helium
and Oxygen on Exercise Performance in COPD: a Randomised Crossover
Trial. Am J Respir Crit Care Med 2006;173(8):865-70.
Juan G, Ramon M, Valia JC, Cortijo J, Rubio E, Morcillo E,
Calverley P. Palliative treatment of dyspnea with
epidural methadone in advanced emphysema. Chest
2005;128(5):3322-8.
Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS,
Calverley PM, Connett JE, Lindmark B, Pauwels RA,
Postma DS, Soriano JB, Szafranski W, Vestbo J. Inhaled
corticosteroids and mortality in chronic obstructive pulmonary
disease. Thorax 2005;60(12):992-7.
Stevenson NJ, Walker PP, Costello RW, Calverley
PM. Lung mechanics and dyspnea during exacerbations of
chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2005;172(12):1510-6.
Calverley P, Pauwels Dagger R, Lofdahl CG,
Svensson K, Higenbottam T, Carlsson LG, Stahl E. Relationship
between respiratory symptoms and medical treatment in exacerbations
of COPD. Eur Respir J 2005;26(3):406-13.
Duffy N, Walker P, Diamantea F, , Davies L. Intravenous
aminophylline in patients admitted to hospital with non-acidotic
exacerbations of chronic obstructive pulmonary disease: a
prospective randomised controlled trial. Thorax
2005;60(9):713-7.
Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley
P; TRISTSAN study group. Early onset of effect of
salmeterol and fluticasone propionate in chronic obstructive
pulmonary disease. Thorax 2005;60(4):301-4.
Calverley P, Pauwels R, Vestbo J, Jones P,
Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids
ANd long-acting beta2 agonists study group. Combined salmeterol and
fluticasone in the treatment of chronic obstructive pulmonary
disease: a randomised controlled trial. Lancet 2003;361:449-56.
Calverley PM, Spencer S, Willits L, Burge PS,
Jones PW; ISOLDE Study Group. Withdrawal from treatment as an
outcome in the ISOLDE study of COPD. Chest
2003;124(4):1350-6.
Calverley PM